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Abstract
Cytogenetic abnormalities are frequently reported in the literature describing the 
presence of chromosomal rearrangements in important cases of acute myeloid leuke-
mia (AML); the rate can reach 50–60% of cases of AML. Cytogenetic abnormalities 
represent an important prognosis factor, their analysis is crucial for AML; cytogenetic 
study permits to classify prognostic groups and indicate the treatment strategy and 
helps to improve the outcome of these patients and to increase their chances of cure. 
Hundreds of uncommon chromosomal aberrations from AML exist. This chapter sum-
marizes chromosomal abnormalities that are common and classifies AML according 
to the World Health Organization (WHO) classifications from 2008 to 2016; we will 
discuss briefly gene mutations detected in normal karyotype (NK) AML by cutting-
edge next-generation sequencing technology, like FLT3-ITD, nucleophosmin (NPM1), 
CCAAT/enhancer-binding protein alpha (CEBPA), and other additional mutations.
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1. Introduction
Acute myeloid leukemia (AML) is characterized by clonal expansion of undif-
ferentiated myeloid precursors, resulting in impaired hematopoiesis and bone 
marrow failure [1].
The discovery of specific chromosomal abnormalities has proved that leukemia 
is a genetic disease on the cellular level and has also guided the way to mapping and 
cloning of genes involved in the leukemic process.
The frequency of cytogenetic abnormalities is reported in the literature describ-
ing the presence of chromosomal rearrangements in important cases of AML; they 
are recognized in approximately 56% of de novo AML in adults [2, 3], and the rate 
can reach 70–80% of the cases of AML in children [4, 5]. At present, cytogenetic 
aberrations detected at the time of AML diagnosis constitute the most common 
basis for predicting clinical outcome [6].
Karyotype analysis must be performed as part of the standard diagnostic 
procedure of AML and have to be reported according to the International System 
for Nomenclature in Human Cytogenetic (ISCN) 3.
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AML appears as a complex and evaluative disease [7, 8]. There are many leu-
kemia genes, most of which are infrequently mutated, and patients typically have 
more than one driver mutation. The AML evolved over time, with multiple compet-
ing clones coexisting at any time [7, 8].
The analysis of cytogenetic abnormalities is indispensable for AML; it represents 
the most important prognosis factor for patients with AML. In fact, cytogenetic 
study helps to classify prognosis groups and guide the treatment strategy and per-
mits to improve the outcome of these patients and to increase their chances of cure.
Many uncommon chromosomal aberrations from AML exist. This chapter 
resumes chromosomal abnormalities that are common in structural and numeri-
cal aberrations. Cytogenetic and mutational data are used to divide patients into 
subgroups defined according to prognostic factors and factors that dictate whether 
allogeneic hematopoietic stem cell transplantation should be performed during an 
initial remission.
2. Recurrent cytogenetic abnormalities
2.1 The t(8;21) (q22;q22.1); RUNX1-RUNX1T1
The t(8;21) (q22;q22.1); RUNX1-RUNX1T1 abnormality is considered as a 
subset with particular clinical and biological specificities. This translocation is 
defined by fusion between the AML1 gene (RUNX1) on chromosome 21 and the 
ETO gene (this translocation can be referred to as the RUNX1T1 gene that encodes 
the CBFA2T1 protein) on chromosome 8. The t(8;21) abnormality is found in 
approximately 5–10% of all AML cases and 10–22% of AML cases with matura-
tion corresponding to the previous FAB class M2. The t(8;21) generates two fusion 
genes, AML1-ETO and ETO-AML1, but only the AML1-ETO transcript transcribed 
from the derivative chromosome 8 is detectable by reverse transcriptase polymerase 
chain reaction (RT-PCR). Patients with t(8,21) are included in the favorable group; 
the prognosis after intensive chemotherapy is better for these patients than for the 
majority of AML patients. The incidence of t(8;21) decreases with age; it is most 
common in children/younger patients and uncommon in patients above 60 years of 
age. Approximately 10–20% of children with AML have this translocation [9].
2.2 The inv(16) (p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
Approximately 5–7% of acute myeloid leukemia patients have an inv(16) 
(p13;q22) or t(16;16)(p13;q22). Molecularly, inv(16)/t(16;16) is the result of the 
juxtaposition of the myosin, heavy chain 11, smooth muscle gene (MYH11) at 16p13 
and the core-binding factor, β subunit gene (CBFB) at 16q22; this juxtaposition cre-
ates the CBFB-MYH11 fusion gene. The genomic breakpoints can be variable within 
CBFB and MYH11; this variability explains why in the literature many differently 
sized CBFB-MYH11 fusion transcript variants have been reported. Type A is the 
more frequent type of fusion reported; it represents more than 85% of fusions, 
and 5–10% of each are type D and type E fusions. This cytogenetic group is char-
acterized by its usually association with high complete remission (CR) rates and a 
relatively favorable outcome [10].
2.3 Acute promyelocytic leukemia with PML-RARA
The of reciprocal translocations (15;17) are usually present on acute promyelo-
cytic leukemia (APL); this translocation involves the PML gene on 15q24 and RARA 
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gene on 17q21 in more than 90% of cases. PML-RARA fusion gene results on the 
derivative chromosome 15.
PML-RARA fusion can also be a result of cases of complex translocations involv-
ing 15, 17, and other partner chromosomes or insertions of 15 into 17 and vice versa. 
Rare variant translocations involving RARA and other partner genes have been 
reported like PLZF, NPM, NuMA, STAT5b, PRKAR1A, FIP1L1, and BCOR [11].
2.4 The t(9;11) (p22;q23)
Acute myeloid leukemia with t(9;11) occurs in 3–5% of cases of AML. The trans-
location t(9;11) (p22;q23) [subsequently referred to as t(9;11)] in acute myeloid 
leukemia resulting in the MLL-MLLT3-fusion protein represents the most common 
translocation involving MLL. MLL gene at 11q23 (HRX) encodes a DNA-binding 
protein that positively regulates expression of target genes, including multiple HOX 
genes, by methylation of histone H3 lys4/chromatin remodeling [12].
2.5 The t(6;9) (p23;q34)
The translocation t(6;9) is a rare recurring cytogenetic aberration and occurs 
in 0.7–1.8% of cases of AML. This translocation is the result of the formation of a 
chimeric fusion gene, DEK-NUP214 (previously known as DEK-CAN). It is associ-
ated with a poor prognosis; the remission is achieved in less than 50% of cases after 
chemotherapy [13].
2.6 The inv(3) (q21q26.2) or t(3;3)(q21;q26.2)
The inv(3) (q21q26.2) or t(3;3)(q21;q26.2) occurring at the long arm of chro-
mosome 3 involves the oncogene EVI1 at 3q26.2 (or its longer form MDS1-EVI1) 
and RPN1 at 3q21, leading to the RPN1-EVI1 fusion transcript. These abnormali-
ties are considered as a separate entity, characterized by an aggressive clinical 
behavior. RPN1 can amplify EVI1 expression resulting in increased cell prolifera-
tion and may impair cell differentiation and be responsible of hematopoietic cell 
transformation [14].
2.7 The t(1;22) (p13;q13)
Acute megakaryoblastic leukemia (AMKL) with t(1;22) (p13;q13) is an 
extremely rare subtype of acute myeloid leukemia that is almost always described 
in infants. The nonrandom association between t(1;22) (p13;q13) and infant AMKL 
was reported by Baruchel et al. [15]. Just after that, the fusion gene OTT-MAL was 
identified in patients with t(1;22).
3. WHO classification for myeloid neoplasm regroups
The World Health Organization (WHO) new classification for myeloid neo-
plasm regroups clinical cytogenetic and molecular criteria, which were associated 
with the morphological and immunophenotypic characteristics used in the clas-
sification recommended by the French-American-British (FAB) cooperative group 
[16]. The current update of the WHO classification provides few changes to the 
existing disease categories. The remaining subcategory AML, not otherwise speci-
fied (NOS), pure erythroid leukemia, requires more than 80% immature erythroid 
precursors with more than 30% proerythroblasts. The most important modification 
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concerned a new category “myeloid neoplasms with germ line predisposition” 
which has been added.
Table 1 summarizes the update of WHO classification of 2016, and Table 2 gives 
more details about the new category “myeloid neoplasms with germ line predisposi-
tion” [17].
3.1 AML with recurrent genetic abnormalities
The revisit interested in the molecular basis of the LMA with inv(3) (q21.3; 
q26.2) or t (3; 3) (q21.3; q26.2) has demonstrated that the repositioning of a GATA2 
enhancer element which is the cause of overexpression of the MECOM gene (EVI1) 
and haploinsufficiency of GATA2 [18, 19].
The revisit added another provisional entity; it is about “AML with BCR-ABL1.” 
Treatment with a tyrosine kinase inhibitor for patients with this abnormality is 
essential. In some cases, distinguishing from blast phase of chronic myeloid leu-
kemia can be difficult; preliminary data suggest that deletion of antigen receptor 
genes (immunoglobulin heavy chain and T-cell receptor), IKZF1, and/or CDKN2A 
would be in favor of the diagnosis of AML rather than chronic myeloid leukemia 
blast phase [20].
When AML is associated with mutated nucleophosmin (NPM1) or biallelic 
mutations of CCAAT/enhancer-binding protein alpha (CEBPA), it is recognized as 
full entities. AML associated with biallelic mutations of CEBPA is the only reported 
as purveyor for the favorable prognosis [21, 22].
Finally, a new provisional entity “AML with mutated RUNX1” (excluding cases 
with changes associated with myelodysplasia) has been introduced. It has been 
associated with distinct clinico-pharmacological features and a poor prognosis 
[23, 24].
3.2 AML with myelodysplasia-related changes
Many criteria were introduced for this category, like the presence of multilineage 
dysplasia, preexisting myeloid disorder, and/or myelodysplasia-related cytogenetic 
changes. The deletion 9q was also removed from the list of myelodysplasia-related 
cytogenetic changes, this modification was done because del9q is usually associated 
with t(8;21), and it also frequently occurs in AML with NPM1 and biallelic CEBPA 
mutations [25, 26].
3.3 AML, not otherwise specified
The subgroup with acute erythroid leukemia and erythroid/myeloid type was 
defined, in the past, by the presence of more than 50% bone marrow erythroid 
precursors and more than 20% myeloblasts among nonerythroid cells; actually 
myeloblasts are always counted as percentage of total marrow cells. The remaining 
subcategory AML, not otherwise specified, pure erythroid leukemia, is defined by 
the presence of 80% immature erythroid precursors with more than 30% proeryth-
roblasts. On AML NOS, FAB classification does not give any prognosis information 
if NMP1 and CEBPA documentation are done [27].
3.4  Myeloid neoplasms with germ line predisposition (synonyms: familial 
myeloid neoplasms; familial myelodysplastic syndromes/acute leukemias)
This new category was recently included; this category needs special inves-
tigations from physicians. He must reconstitute the patient and family history. 
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Myeloid neoplasms with germ line predisposition (see Table 2)
AML and related neoplasms AML and related neoplasms (cont’d)
AML with recurrent genetic abnormalities Acute myelomonocytic leukemia
AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 Acute monoblastic/monocytic leukemia
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); 
CBFB-MYH11
Pure erythroid leukemia#
Acute promyelocytic leukemia with PML-RARA* Acute megakaryoblastic leukemia
AML with t(9;11)(p21.3;q23.3); MLLT3-KMT2A† Acute basophilic leukemia
AML with t(6;9)(p23;q34.1); DEK-NUP214 Acute panmyelosis with myelofibrosis
AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); 
GATA2,MECOM(EVI1)
Myeloid sarcoma
AML (megakaryoblastic) with t(1;22)(p13.3;q13.3); 
RBM15-MKL1‡
Myeloid proliferations related to Down 
syndrome
Provisional entity: AML with BCR-ABL1 Transient abnormal myelopoiesis
AML with mutated NPM1§ Myeloid leukemia associated with Down 
syndrome
AML with biallelic mutations of CEBPA§ Blastic plasmacytoid dendritic cell neoplasm
Provisional entity: AML with mutated RUNX1 Acute leukemias of ambiguous lineage
AML with myelodysplasia-related changes‖ Acute undifferentiated leukemia
Therapy-related myeloid neoplasms¶ MPAL with t(9;22)(q34.1;q11.2); BCR-ABL1**
AML, NOS MPAL with t(v;11q23.3); KMT2A rearranged
AML with minimal differentiation MPAL, B/myeloid, NOS
AML without maturation MPAL, T/myeloid, NOS
AML with maturation
For a diagnosis of AML, a marrow blast count of ≥20% is required, except for AML with the recurrent genetic 
abnormalities t(15;17), t(8;21), inv(16), or t(16;16).
MPAL, mixed phenotype acute leukemia; NK, natural killer.
*Other recurring translocations involving RARA should be reported accordingly: for example, AML with t(11;17)
(q23;q12); ZBTB16-RARA; AML with t(11;17)(q13;q12); NUMA1-RARA; AML with t(5;17)(q35;q12); NPM1-
RARA; or AML with STAT5B-RARA (the latter having a normal chromosome 17 on conventional cytogenetic analysis).
†Other translocations involving KMT2A (MLL) should be reported accordingly: for example, AML with t(6;11)
(q27;q23.3); MLLT4-KMT2A; AML with t(11;19)(q23.3;p13.3); KMT2A-MLLT1; AML with t(11;19)
(q23.3;p13.1); KMT2A-ELL; and AML with t(10;11)(p12;q23.3); MLLT10-KMT2A.
‡Rare leukemia most commonly occurring in infants.
§Diagnosis is made irrespective of the presence or absence of multilineage dysplasia.
‖At least 20% (≥20%) blood or marrow blasts and any of the following: previous history of MDS or MDS/MPN; 
myelodysplasia-related cytogenetic abnormality (see list below); multilineage dysplasia; and the absence of both 
prior cytotoxic therapy for unrelated disease and aforementioned recurring genetic abnormalities. Cytogenetic 
abnormalities sufficient to diagnose AML with myelodysplasia-related changes are complex karyotype (defined as 
three or more chromosomal abnormalities in the absence of one of the WHO-designated recurring translocations 
or inversions, that is, t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23.3), t(6;9), inv(3) or t(3;3); AML with 
BCR-ABL1); unbalanced abnormalities: −7 or del(7q); −5 or del(5q); i(17q) or t(17p); −13 or del(13q); del(11q); 
del(12p) or t(12p); idic(X)(q13); and balanced abnormalities: t(11;16)(q23.3;p13.3); t(3;21)(q26.2;q22.1); t(1;3)
(p36.3;q21.2); t(2;11)(p21;q23.3); t(5;12)(q32;p13.2); t(5;7)(q32;q11.2); t(5;17)(q32;p13.2); t(5;10)(q32;q21.2); 
t(3;5)(q25.3;q35.1).
¶Cases should be classified with the related genetic abnormality given in the diagnosis.
#The former subgroup of acute erythroid leukemia and erythroid/myeloid type (≥50% bone marrow erythroid 
precursors and ≥ 20% myeloblasts among nonerythroid cells) was removed; myeloblasts are now always counted 
as percentage of total marrow cells. The remaining subcategory AML, NOS, pure erythroid leukemia, requires the 
presence of >80% immature erythroid precursors with ≥30% proerythroblasts.
**BCR-ABL1+ leukemia may present as MPAL; treatment should include a tyrosine kinase inhibitor.
Table 1. 
Myeloid neoplasms with germ line predisposition, AML and related precursor neoplasms, and acute leukemias 
of ambiguous lineage (WHO 2016).
Chromosomal Abnormalities
6
Affected patients, including their families, should benefit from genetic counseling 
with a counselor familiar with these disorders.
4. European leukemia net 2017 recommendations
The WHO 2008 and 2016 classifications incorporated modifications that 
allowed for a greater number of patients to be classified into the category of AML 
[28]. However, in 2010, an international expert panel, on behalf of the European 
WHO classification
Classification*
Myeloid neoplasms with germ line predisposition without a preexisting disorder or organ dysfunction
AML with germ line CEBPA mutation
Myeloid neoplasms with germ line DDX41 mutation†
Myeloid neoplasms with germ line predisposition and preexisting platelet disorders
Myeloid neoplasms with germ line RUNX1 mutation†
Myeloid neoplasms with germ line ANKRD26 mutation†
Myeloid neoplasms with germ line ETV6 mutation†
Myeloid neoplasms with germ line predisposition and other organ dysfunction
Myeloid neoplasms with germ line GATA2 mutation
Myeloid neoplasms associated with bone marrow failure syndromes
Juvenile myelomonocytic leukemia associated with neurofibromatosis, Noonan syndrome, or Noonan 
syndrome-like disorders
Myeloid neoplasms associated with Noonan syndrome
Myeloid neoplasms associated with Down syndrome†
Guide for molecular genetic diagnostics‡
Myelodysplastic predisposition/acute leukemia predisposition syndromes
CEBPA, DDX41, RUNX1, ANKRD26, ETV6, GATA2, SRP72, 14q32.2 genomic duplication (ATG2B/GSKIP)
Cancer predisposition syndromes§
Li-Fraumeni syndrome (TP53)
Germ line BRCA1/BRCA2 mutations
Bone marrow failure syndromes
Dyskeratosis congenita (TERC, TERT)
Fanconi anemia
*Recognition of familial myeloid neoplasms requires that physicians take a thorough patient and family history to 
assess for typical signs and symptoms of known syndromes, including data on malignancies and previous bleeding 
episodes.
†Lymphoid neoplasms are also reported.
‡Molecular genetic diagnostics are guided by a detailed patient and family history; diagnostics should be performed 
in close collaboration with a genetic counselor; patients with a suspected heritable myeloid neoplasm, who test 
negative for known predisposition genes, should ideally be entered on a research study to facilitate new syndrome 
discovery.
§Mutations in genes associated with cancer predisposition genes such as TP53 and BRCA1/2 appear to be frequent in 
therapy-related myeloid neoplasms.
Table 2. 
WHO classification of myeloid neoplasms with germ line predisposition and guide for molecular genetic 
diagnostics.
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Leukemia Net (ELN), established recommendations for diagnosis and manage-
ment of acute myeloid leukemia. These recommendations have been widely used in 
practice, within clinical trials, and by regulatory agencies. Recently, a big progress 
has been made in understanding disease pathogenesis and in the development of 
diagnostic assays and novel therapies. The ELN recommendations were updated, 
and new recommendations were published.
The goal of ELN is to subdivide genetic categories on prognostic groups to make 
easier correlations between genetic abnormalities and clinical characteristics and 
outcomes.
Although a subsequent study elicited a longer overall survival (OS) in the inter-
mediate I group than in the intermediate II group, both groups were prognostically 
indistinguishable in the more aged patients, who represent the majority of AML 
cases [25].
The new recommendation of ELN identifies three groups (favorable, intermedi-
ate, adverse) with some changes. It was proved that in AML with NPM1 or biallelic 
CEBPA mutations, the presence of coexisting chromosomal abnormalities does not 
appear to modify the prognostic [29].
The latest published research has confirmed that the relapse rate and outcomes 
associated with FLT3-ITD are related to the ITD allele ratio. Studies showed that 
patients with NPM1 and FLT3-ITD mutation with a low allelic ratio (<0.5) (FLT3-
ITDlow) have the same response rate as patients with NPM1 mutation but no 
FLT3-ITD; they are classified in the favorable group.
The latest findings from recent research suggest that the presence of the FLT3 
mutation alone is not sufficient to classify patients into unfavorable prognostic 
groups and that patients with a NPM1 and FLT3-ITD mutation with a low allelic 
ratio (<0.5) (FLT3-ITDlow) have the same result as patients with a NPM1 mutation 
without FLT3-ITD; they are included in a favorable group [30, 31].
Patients with a high ratio are classified in the unfavorable group when they have 
wild-type NPM1 and FLT3-ITD with a high (>0.5) allelic ratio (FLT3-ITDhigh); 
those patients have a poor outcome, but recently the use of FLT3 inhibitors can 
improve prognosis [32].
Other abnormalities were introduced to adverse-risk group like RUNX1, ASXL1, 
and TP53 mutations and monosomal karyotype [33, 34].
5. Medical Research Council (MRC) cytogenetic classification
In the past Medical Research Council (MRC) cytogenetic classification was 
developed, by analyzing a cohort of 1612 children and younger adults (55 years) 
treated in the MRC AML10 trial; this work was realized more than a decade ago and 
distinguishes three cytogenetic risk groups [35]. The first group includes patients 
with t(15;17), t(8;21), and inv(16), irrespective of the presence of additional 
cytogenetic changes; these categories were assigned to the “favorable-risk” group. 
The 2sd group concerns patients who have none of these aberrations and who have 
abn(3q), del (5q), 5/7, or complex karyotype (five or more unbound cytogenetic 
abnormalities). This group was considered as an “adverse risk.” Other patients, 
those with normal karyotype (NK) and other structural or numerical abnormali-
ties, were in the “intermediate-risk” group. In the original MRC study, patients 
having infrequent or rare abnormalities were not considered individually and were 
assigned to the intermediate-risk group [36].
Advances in molecular biology have provided important insights into molecular 
abnormalities that previously were poorly understood.
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Significant advances in technology, including chromosome banding, with 
fluorescence/chromosome in situ hybridization, or other analyses like array com-
parative network genomic hybridization, genome breakpoints cloning and Sanger 
sequencing of candidate genes and profiling of single nucleotide polymorphism, 
and even whole-genome sequencing (WGS), whole-exome sequencing (WES), and 
RNA sequencing have all contributed to incremental improvements in understand-
ing the genetic basis of the AML.
The whole-genome sequencing for AML confirmed that it is a complex and 
instable disease. There are many leukemia genes, most of which are infrequently 
mutated, and patients typically have many driver mutations. The evolution is 
characterized by emergence of many competing clones which can coexist at any 
time.
Figure 1 illustrates different genes and clones coexisting in the same patient [17].
The Cancer Genome Atlas (TCGA) consortium analyzed 200 AML patients by 
whole-genome or whole-exome sequencing and identified 23 genes as “significantly 
mutated” at a higher-than-expected frequency [37].
Recently research confirmed that normal karyotype AML is a very heteroge-
neous group; many gene mutations were detected in normal karyotype AML by 
cutting-edge next-generation sequencing NGS technology, like FLT3-ITD, NPM1, 
CEBPA, and other additional mutations.
DNMT3A and RUNX1 mutations represent the most important predictors of 
shorter overall survival in AML patients aged less than 60 years and particularly in 
those with intermediate-risk cytogenetic. NPM1 mutations in the absence of FLT3-ITD, 
mutated TP53, and biallelic CEBPA mutations were identified as important molecular 
prognosticators of OS irrespective of patient age. Researching these gene mutations is 
important. It can be helpful on diagnosis and it can be a molecular marker of prognosis, 
predictive for response of treatment, and used also for disease monitoring.
Figure 1. 
Molecular classes of AML and concurrent gene mutations in adult patients up to the age of ~65 years. For each 
AML class denoted in the pie chart, frequent co-occurring mutations are shown in the respective boxes. Data 
on the frequency of genetic lesions are compiled from the databases of the British Medical Research Council 
(MRC) and the German-Austrian AML study group (AMLSG) and from selected studies. It indicates cohesin 
genes including RAD21 (10%), SMC1A (5%), and SMC3 (5%); inv(16)(p13.1q22) or t(16;16)(p13.1;q22); 
CBFB-MYH11; and inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1), and TP53 mutations 
are found in 45% and complex karyotypes in 70% of this class.
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It has been proven in previous studies that patients with cytogenetically normal 
AML or intermediate-risk abnormalities have more additional gene mutations than 
patients with favorable or unfavorable abnormal cytogenetic and especially those 
with balanced translocations [38].
Elderly patients have more driver gene mutations than younger patients. Older 
patients are characterized by having more alterations in specific genes including 
TET2, RUNX1, ASXL1, and SRSF2. All this genes have recently been implicated 
in age-related clonal hematopoiesis. These data contribute to highlight our under-
standing of differences in AML biology between younger and older patients [39].
5.1 Mutations in the fms-related tyrosine kinase 3 gene (FLT3)
Mutations in the fms-related tyrosine kinase 3 gene (FLT3) are present in 30% 
of patients having AML [40]. In approximately three quarters of these patients, the 
mutation found concerns FLT3 internal tandem duplication mutation (ITD sub-
type). This mutation is the result of the duplication between 3 and more than 100 
amino acids located in the juxtamembrane region. Studies confirmed that patients 
with AML having ITD mutations had a poor outcome with high risk to relapse. The 
rate of response is related to the ratio of mutant. In fact, the prognosis is poorer 
when there is a high ratio of mutant to wild-type FLT3 alleles. This permits the 
development of specific treatment of such FLT3 inhibitors.
In fact, recent studies showed that the use of several specific tyrosine kinase 
inhibitors improves outcome and clinical trials that are underway [41, 42]. The 
inclusion of such inhibitors in therapeutic strategy with alloHCT might further 
improve future outcome of patients with FLT3-ITD AML [43].
5.2 Nucleophosmin protein mutation
NPM1 mutation is detected approximately in 30% of cases of AML with normal 
karyotype NPM; it is an aberrant cytoplasmic localization of the nucleoplasmin protein. 
Nuclephosmin protein mutation also named as B23 or numatrin, is a nucleocytoplasmic 
shuttling protein that constantly exchanges between the nucleus and cytoplasm [44].
5.3 CCAAT/enhancer-binding protein alpha mutations
CCAAT/enhancer-binding protein alpha mutations in AML are associated with 
favorable prognosis and are divided into N- and C-terminal mutations (double-
mutated). CEBPA mutation occurs in 5–10% of cases of acute myeloid leukemia. Recent 
studies have shown that CEBPA-double-mutated (CEBPA-dm) cases, rather than single 
mutants, are associated with a common gene expression signature and a relatively 
favorable outcome. Based on these features, CEBPA-dm AML has been recognized as a 
separate entity in the revised World Health Organization 2016 classification [45].
5.4 Recurrent mutations in isocitrate dehydrogenase 1/2 (IDH1/IDH2)
Recurrent mutations in isocitrate dehydrogenase 1/2 (IDH1/IDH2) occur in 
~12% of patients with acute myeloid leukemia with normal karyotype. Mutated 
IDH2 proteins neomorphically synthesize 2-hydroxyglutarate resulting in DNA 
and histone hypermethylation, which leads to blocked cellular differentiation. 
The incidence of this gene mutation increases with age [46]. Enasidenib (AG-221/
CC-90007) and ivosidenib (AG-120) are first-in-class, oral, selective, small-mole-
cule inhibitors of IDH2- and IDH1-mutant enzymes, respectively.
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5.5 DNMT3A mutation
DNA methyltransferase (DNMT) 3A catalyzes the addition of methyl groups to 
the cytosine residue of CpG dinucleotides in DNA; the role of DNMT3A is to encode 
the DNMT. DNMT3A is constituted by three main structure domains: an ATRX, 
DNMT3, and DNMT3L-type zinc finger domain, a proline-tryptophan-tryptophan-
proline domain, and the methyltransferase (MTase) domain.
The proline-tryptophan-tryptophan-proline domain targets the enzyme to 
nucleic acid, whereas the zinc finger domain is responsible of mediating protein-
protein and interacting with the transcription factors Myc and RP58, the hetero-
chromatin protein HP1, histone deacetylases, and the histone methyltransferase 
Suv39h1 [47].
DNMT3A mutation confers a specific clinical and biological feature, it is associ-
ated with poor prognostic, and it represents an unfavorable risk factor in AML 
patients independent of others risk factors like age, WBC counts, karyotype, and 
other genetic markers.
6. Conclusion
The update of WHO classification and ELN recommendations is useful for 
physicians; it can help to better subdivide risk groups and propose adequate treat-
ment for each group [28]. On the other hand, an increasing understanding of 
molecular aberrations that triggers the development of AML and growing use of 
next-generation sequencing are advancing the development of investigational drugs 
against potential driver mutations in AML.
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